These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 31808894)
1. In MDS, is higher risk higher reward? Sanz GF Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):381-390. PubMed ID: 31808894 [TBL] [Abstract][Full Text] [Related]
2. Does early diagnosis and treatment of myelodysplastic syndromes make a difference? Steensma DP Best Pract Res Clin Haematol; 2019 Dec; 32(4):101099. PubMed ID: 31779983 [TBL] [Abstract][Full Text] [Related]
3. Optimal sequencing of treatments for patients with myelodysplastic syndromes. Itzykson R; Fenaux P Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268 [TBL] [Abstract][Full Text] [Related]
5. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents. Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031 [TBL] [Abstract][Full Text] [Related]
6. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Xie M; Jiang Q; Xie Y Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977 [TBL] [Abstract][Full Text] [Related]
7. Evolving treatment options of myelodysplastic syndromes. Verbeek W; Ganser A Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297 [TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Garcia-Manero G Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090 [TBL] [Abstract][Full Text] [Related]
9. Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. Falconi G; Fabiani E; Criscuolo M; Fianchi L; Finelli C; Cerqui E; Pelosi E; Screnci M; Gurnari C; Zangrilli I; Postorino M; Laurenti L; Piciocchi A; Testa U; Lo-Coco F; Voso MT Leuk Res; 2019 Sep; 84():106191. PubMed ID: 31386932 [TBL] [Abstract][Full Text] [Related]
10. Update on the pharmacotherapy for myelodysplastic syndromes. Duong VH; Komrokji RS; List AF Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144 [TBL] [Abstract][Full Text] [Related]
11. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299 [TBL] [Abstract][Full Text] [Related]
12. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis. Qin Y; Kuang P; Zeng Q; Wu Y; Liu T Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of higher risk myelodysplastic syndromes]. Usuki K Rinsho Ketsueki; 2019; 60(9):1131-1139. PubMed ID: 31597836 [TBL] [Abstract][Full Text] [Related]
14. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003 [TBL] [Abstract][Full Text] [Related]
15. Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents. Odenike O Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):460-469. PubMed ID: 29222294 [TBL] [Abstract][Full Text] [Related]
16. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320 [TBL] [Abstract][Full Text] [Related]
17. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Schroeder T; Rautenberg C; Haas R; Germing U; Kobbe G Int J Hematol; 2018 Feb; 107(2):138-150. PubMed ID: 29143282 [TBL] [Abstract][Full Text] [Related]
18. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes? Steensma DP Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541 [TBL] [Abstract][Full Text] [Related]
19. New investigational combinations for higher-risk MDS. Koenig KL; Borate U Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):368-374. PubMed ID: 36485141 [TBL] [Abstract][Full Text] [Related]
20. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]